News

Prof. Shinsuke Sando at THE UNIVERSITY OF TOKYO and TAGCyx ANNOUNCES THE RESEARCH COLLABORATION of THE TECHNOLOGICAL IMPROVEMENT OF XENOLIGO®

March 22nd, 2021

Prof. Shinsuke Sando at the university of Tokyo

TAGCyx biotechnologies Inc.

 

Prof. Shinsuke Sando at the university of Tokyo, Tokyo, and TAGCyx biotechnologies Inc., Tokyo, announced entering into a research collaboration of the technological improvement of Xenoligo®.

Prof. Shinsuke Sando is an expert in functional molecules: an artificial cell growth factor, an artificial peptide, which is applicable to understanding the phenomena of life.

TAGCyx has invented artificial nucleic acid base-pair technology that enables to produce high avidity and selective functional DNA aptamers “Xenoligo®”.

Both parties intend to collaborative research regarding technological improvement of developing Xenoligo® to be excellent medicine.

 

For further information, please contact:

Prof. Shinsuke Sando

E-Mail: ssando@chembio.t.u-tokyo.ac.jp

 

TAGCyx biotechnologies Inc.

E-Mail: info@tagcyx.com

TAGCyx announces execution of worldwide exclusive supply of proprietary artificial Ds amidite and patent license agreement with Otsuka Chemical Co., Ltd.

TAGCyx executed worldwide exclusive supply of its proprietary Ds amidite and patent license agreement with Otsuka Chemical Co., Ltd. (Osaka, Japan) (“Otsuka Chemical”) in order for TAGCyx and their alliance partners to develop and commercialize Xenoligo® DNA aptamers containing the artificial base Ds.

TAGCyx is a preclinical stage drug development company based in Tokyo which is developing and commercializing DNA aptamers applying world leading artificial nucleic acid base-pair technology. The Ds is a unique artificial nucleic acid which makes feasible to generate DNA aptamers with high affinity and selectivity to target molecule. This proprietary technology, Xenoligo® is applicable to generate therapeutic drugs and diagnostic agents and also improve functionality of some medical devices, with high performance and high functionality. For advancing pipeline projects of TAGCyx and their alliance partners to preclinical (GLP) and clinical (GMP ) stages of the development, Otsuka Chemical will make quality assured Ds amidite available at commercial scale by developing scale up manufacturing process of  production system.

Under this agreement, TAGCyx grants Otsuka Chemical an exclusive patent license for the manufacturing and an exclusive supply right of Ds amidite for development and commercialization of Xenoligo®.

Otsuka Chemical manufactures and sells chemical products including active pharmaceutical ingredients and their intermediates, and possesses the high quality organic synthesis technologies and production facility cultivated over many years. Therefore, by partnering with Otsuka Chemical, TAGCyx will be able to strongly promote and advance product development and secure large scale quality assured manufacturing of Xenoligo® aptamers.

 

Notes: Xenoligo® is a trademark registered by TAGCyx Biotechnologies Inc.

 

For further information, please contact:

TAGCyx biotechnologies Inc.

TEL:+81-3-6407-1672

E-Mail:  info@tagcyx.com

Prof. Taiichi Sakamoto at CHIBA INSTITUTE TECHNOLOGY and TAGCyx ANNOUNCES THE RESEARCH COLLABORATION of THE STRUCTURAL ANALYSIS OF XENOLIGO®

February 19th, 2021

Prof. Taiichi Sakamoto at Chiba Institute Technology

TAGCyx biotechnologies Inc.

 

Prof. Taiichi Sakamoto at Chiba Institute Technology, Chiba, and TAGCyx biotechnologies Inc., Tokyo, announced entering into a research collaboration of the structural analysis of Xenoligo®.

Prof. Taiichi Sakamoto is an expert in nucleic acid-protein interaction using structural analysis.

TAGCyx has invented artificial nucleic acid base-pair technology that enables to produce high avidity and selective functional DNA aptamers “Xenoligo®”.

Both parties intend to collaborative research regarding the recognition mechanism of Xenoligo® against target proteins based on the structural analysis.

 

For further information, please contact:

Prof. Taiichi Sakamoto

E-Mail: taiichi.sakamoto@p.chibakoudai.jp

 

TAGCyx biotechnologies Inc.

E-Mail: info@tagcyx.com

SBI Pharmaceuticals and TAGCyx ANNOUNCES THE RESEARCH AND DEVELOPMENT COLLABORATION OF INOVATIVE CANCER THERAPY

November 25, 2020

 

SBI Pharmaceuticals Co., Ltd.

TAGCyx biotechnologies Inc.

SBI Pharmaceuticals and TAGCyx ANNOUNCES THE RESEARCH AND DEVELOPMENT COLLABORATION OF INOVATIVE CANCER THERAPY

 

 

SBI Pharmaceuticals Co., Ltd., Tokyo, and TAGCyx biotechnologies Inc., Tokyo, announced entering into a research and develop collaboration to develop innovative products in the field of cancer treatment.

SBI Pharmaceuticals is specialized in the application of 5-ALA (5-aminolevulinic acid) and is dedicated to provide innovation for a wide range of health applications in the healthcare and health food field in order to help improve the health and quality of human life all over the world.

TAGCyx has invented artificial nucleic acid base-pair technology that enables to produce high affinity and selective DNA aptamers “Xenoligo®”.

By combining SBI Pharmaceuticals’ technology and TAGCyx’s Xenoligo®, both companies intend to develop novel technologies in oncology arena.

As part of the joint research and development, TAGCyx will receive research and development funds, multiple milestones at certain steps during the development as well as sales related royalties accordingly.

(*1) 5-aminolevulinic acid (5-ALA):  An amino acid produced in mitochondria. It is an important substance that serves as a functional molecule related to energy production in the form of heme and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in food such as shochu lees, red wine and Asian ginseng. It is also known as a material forming chloroplasts in plants.

 

For further information, please contact:

SBI Pharmaceuticals Co., Ltd.:

Tel: 03-6229-0095  E-Mail:  info_ala@sbigroup.co.jp

 

TAGCyx biotechnologies Inc.

E-Mail:  info@tagcyx.com